Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free PHIO Stock Alerts

Phio Pharmaceuticals (PHIO) Financials

Phio Pharmaceuticals logo
$1.04 -0.02 (-1.89%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$1.05 +0.01 (+1.35%)
As of 08/7/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Phio Pharmaceuticals

Annual Income Statements for Phio Pharmaceuticals

This table shows Phio Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -10 -11 -12 -7.36 -8.91 -8.79 -13 -11 -11 -7.15 -8.70
Consolidated Net Income / (Loss)		 -10 -8.99 -12 -7.36 -8.91 -8.79 -13 -11 -11 -7.15 -8.70
Net Income / (Loss) Continuing Operations		 -10 -8.99 -12 -7.36 -8.91 -8.79 -13 -11 -11 -7.15 -8.70
Total Pre-Tax Income 		-10 -8.99 -14 -7.36 -8.91 -8.79 -13 -11 -11 -7.15 -8.70
Total Operating Income		 -10 -9.02 -14 -7.36 -8.99 -8.79 -14 -11 -11 -7.39 -9.22
Total Gross Profit		 0.03 0.02 0.02 0.14 0.02 0.00 0.00 0.00 0.01 0.00 0.00
Total Revenue		 0.03 0.02 0.02 0.14 0.02 0.00 0.00 0.00 0.01 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 10 9.03 14 7.50 9.01 8.79 14 11 11 7.39 9.22
Selling, General & Admin Expense		 3.35 3.62 4.01 3.18 4.71 5.08 4.63 4.45 4.37 3.74 4.60
Research & Development Expense		 6.93 5.42 10 4.33 4.30 3.72 8.89 7.01 6.33 3.64 4.62
Total Other Income / (Expense), net		 0.01 0.02 -0.01 0.00 0.08 -0.00 0.22 -0.02 -0.01 0.24 0.52
Interest & Investment Income		 0.02 0.02 - - - -0.00 - - - 0.23 0.52
Other Income / (Expense), net		 -0.00 0.01 -0.01 0.00 0.08 -0.00 0.22 -0.02 - 0.01 0.00
Basic Earnings per Share		 ($2.10) ($16.41) ($5.52) ($57.46) ($19.33) ($1.92) ($12.43) - ($46.76) ($9.08) ($1.45)
Weighted Average Basic Shares Outstanding		 4.97M 674.61K 2.26M 128.09K 460.81K 4.59M 1.07M 1.15M 231.51K 787.47K 5.98M
Weighted Average Diluted Shares Outstanding		 4.97M 674.61K 2.26M 128.09K 460.81K 4.59M 1.07M 1.15M 231.51K 4.78M 11.62M
Weighted Average Basic & Diluted Shares Outstanding		 4.97M 674.61K 2.26M 128.09K 460.81K 4.59M 12.83M 1.15M 4.59M 4.78M 11.62M

Quarterly Income Statements for Phio Pharmaceuticals

This table shows Phio Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.90 -2.15 -1.85 -1.52 -1.63 -1.77 -2.17 -2.39 -2.37 -4.00 -4.14
Consolidated Net Income / (Loss)		 -1.90 -2.15 -1.85 -1.52 -1.63 -1.77 -2.17 -2.39 -2.37 -4.00 -4.14
Net Income / (Loss) Continuing Operations		 -1.90 -2.15 -1.85 -1.52 -1.63 -1.77 -2.17 -2.39 -2.37 -4.00 -4.14
Total Pre-Tax Income 		-1.90 -2.15 -1.85 -1.52 -1.63 -1.77 -2.17 -2.39 -2.39 -4.00 -4.14
Total Operating Income		 -1.90 -2.21 -1.91 -1.59 -1.67 -1.87 -2.31 -2.51 -2.53 -4.17 -4.27
Total Gross Profit		 0.01 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 0.01 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 1.90 2.21 1.91 1.59 1.67 1.87 2.31 2.51 2.53 4.17 4.27
Selling, General & Admin Expense		 0.77 1.06 1.05 0.95 0.69 0.99 1.24 1.32 1.06 1.37 1.19
Research & Development Expense		 1.01 1.15 0.87 0.64 0.99 0.89 1.07 1.18 1.48 2.79 3.08
Total Other Income / (Expense), net		 -0.00 0.06 0.07 0.07 0.05 0.10 0.14 0.11 0.14 0.16 0.13
Interest & Investment Income		 - - - 0.07 - 0.13 0.14 0.11 - 0.16 0.13
Other Income / (Expense), net		 - 0.00 0.07 0.00 -0.06 -0.02 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 ($8.19) ($0.47) ($3.62) ($1.54) ($2.06) ($0.41) ($0.45) ($0.44) ($0.40) ($0.34) ($0.36)
Weighted Average Basic Shares Outstanding		 231.51K 4.58M 510.19K 990.03K 787.47K 4.31M 4.79M 5.47M 5.98M 11.62M 11.62M
Weighted Average Diluted Shares Outstanding		 231.51K 4.58M 510.19K 1.06M 4.78M 4.80M 5.73M 10.76M 11.62M 11.62M 11.62M
Weighted Average Basic & Diluted Shares Outstanding		 4.59M 4.59M 860.72K 1.06M 4.78M 4.80M 5.73M 10.76M 11.62M 11.62M 11.62M

Annual Cash Flow Statements for Phio Pharmaceuticals

This table details how cash moves in and out of Phio Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.38 7.79 -9.33 11 -7.95 7.31 9.81 -12 -3.34 -3.11 16
Net Cash From Operating Activities		 -7.32 -7.76 -9.51 -7.52 -8.65 -8.80 -12 -12 -11 -7.11 -7.98
Net Cash From Continuing Operating Activities		 -7.32 -7.76 -9.51 -7.52 -8.65 -8.80 -12 -12 -11 -7.11 -7.98
Net Income / (Loss) Continuing Operations		 -10 -8.99 -12 -7.36 -8.91 -8.79 -13 -11 -11 -7.15 -8.70
Consolidated Net Income / (Loss)		 -10 -8.99 -12 -7.36 -8.91 -8.79 -13 -11 -11 -7.15 -8.70
Depreciation Expense		 0.08 0.05 0.07 0.08 0.07 0.07 0.08 0.07 0.06 0.00 0.00
Amortization Expense		 - - - - - - 0.12 0.12 0.13 0.03 0.00
Non-Cash Adjustments To Reconcile Net Income		 1.76 0.75 5.02 0.28 0.41 0.14 0.13 0.29 0.29 0.11 0.48
Changes in Operating Assets and Liabilities, net		 1.07 0.43 -2.15 -0.52 -0.21 -0.22 1.11 -1.13 -0.40 -0.10 0.24
Net Cash From Investing Activities		 -5.56 5.35 -0.10 -0.01 -0.07 -0.02 -0.05 -0.12 -0.01 0.01 -0.01
Net Cash From Continuing Investing Activities		 -5.56 5.35 -0.10 -0.01 -0.07 -0.02 -0.05 -0.12 -0.01 0.01 -0.01
Purchase of Property, Plant & Equipment		 -0.06 -0.00 -0.20 -0.01 -0.07 -0.02 -0.05 -0.12 -0.01 -0.00 -0.01
Sale of Property, Plant & Equipment		 - - - - - - - - 0.00 0.01 0.00
Net Cash From Financing Activities		 9.50 10 0.29 19 0.77 16 22 -0.03 7.41 4.00 24
Net Cash From Continuing Financing Activities		 9.50 10 0.29 19 0.77 16 22 -0.03 7.41 4.00 24
Issuance of Common Equity		 9.30 10 0.29 19 0.71 12 20 0.00 7.45 0.00 18
Other Financing Activities, net		 0.20 - 0.00 0.11 0.07 3.85 2.15 -0.03 -0.04 4.00 5.73
Cash Interest Paid		 - - 0.00 - 0.01 0.01 - - 0.01 0.01 0.00

Quarterly Cash Flow Statements for Phio Pharmaceuticals

This table details how cash moves in and out of Phio Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 0.03 -2.02 -1.78 0.69 -0.01 7.90 -2.50 -0.07 10 -4.00 -4.04
Net Cash From Operating Activities		 -2.37 -2.01 -1.78 -1.95 -1.37 -1.28 -2.54 -2.09 -2.08 -4.00 -4.04
Net Cash From Continuing Operating Activities		 -2.37 -2.01 -1.78 -1.95 -1.37 -1.28 -2.54 -2.09 -2.08 -4.00 -4.04
Net Income / (Loss) Continuing Operations		 -1.90 -2.15 -1.85 -1.52 -1.63 -1.77 -2.17 -2.39 -2.37 -4.00 -4.14
Consolidated Net Income / (Loss)		 -1.90 -2.15 -1.85 -1.52 -1.63 -1.77 -2.17 -2.39 -2.37 -4.00 -4.14
Depreciation Expense		 0.01 0.00 0.00 - - 0.00 - 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.10 0.04 -0.02 0.05 0.04 0.04 0.05 0.11 0.27 0.32 0.28
Changes in Operating Assets and Liabilities, net		 -0.62 0.07 0.09 -0.48 0.22 0.45 -0.43 0.19 0.02 -0.32 -0.18

Annual Balance Sheets for Phio Pharmaceuticals

This table presents Phio Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 11 13 4.10 15 8.04 16 25 13 9.36 5.74 21
Total Current Assets		 11 13 3.83 15 7.30 15 25 12 9.32 5.74 21
Cash & Equivalents		 5.12 13 3.58 15 6.93 14 24 12 8.49 5.38 21
Prepaid Expenses		 0.31 0.15 0.20 0.22 0.32 0.87 0.62 0.62 0.83 0.35 0.45
Plant, Property, & Equipment, net		 0.16 0.11 0.25 0.17 0.21 0.16 0.13 0.18 0.01 0.00 0.01
Total Noncurrent Assets		 0.02 0.18 0.02 0.00 0.53 0.42 0.31 0.19 0.04 0.00 0.00
Total Liabilities & Shareholders' Equity		 11 13 4.10 15 8.04 16 25 13 9.36 5.74 21
Total Liabilities		 2.27 2.54 2.27 1.74 2.29 2.72 3.24 1.97 1.63 1.02 1.34
Total Current Liabilities		 2.27 2.54 2.27 1.74 1.88 2.20 3.07 1.94 1.63 1.02 1.34
Accounts Payable		 1.16 0.92 0.51 0.55 0.81 0.73 0.28 0.78 0.66 0.25 0.44
Accrued Expenses		 1.11 1.63 1.75 1.19 0.96 1.35 2.66 1.03 0.94 0.76 0.91
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.41 0.53 0.17 0.04 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 8.89 11 1.83 14 5.75 13 22 11 7.73 4.72 20
Total Preferred & Common Equity		 8.89 11 1.83 14 5.75 13 22 11 7.73 4.72 20
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 - - - 0.00 0.00
Total Common Equity		 8.89 11 1.83 14 5.75 13 22 11 7.73 4.72 20
Common Stock		 66 73 80 99 101 117 139 139 147 151 175
Retained Earnings		 -57 -66 -79 -86 -95 -104 -117 -128 -139 -146 -155

Quarterly Balance Sheets for Phio Pharmaceuticals

This table presents Phio Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 9.54 6.85 5.30 5.87 13 11 12 17 14
Total Current Assets		 9.33 6.85 5.29 5.86 13 11 11 17 14
Cash & Equivalents		 8.41 6.48 4.70 5.39 13 11 11 17 13
Prepaid Expenses		 0.87 0.37 0.59 0.47 0.16 0.52 0.79 0.37 1.30
Plant, Property, & Equipment, net		 0.14 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01
Total Noncurrent Assets		 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 9.54 6.85 5.30 5.87 13 11 12 17 14
Total Liabilities		 2.33 1.25 1.52 0.92 1.27 1.21 1.67 0.95 1.71
Total Current Liabilities		 2.33 1.25 1.52 0.92 1.27 1.21 1.67 0.95 1.71
Accounts Payable		 0.17 0.32 0.34 0.18 0.43 0.24 0.52 0.26 0.90
Accrued Expenses		 2.08 0.93 1.19 0.74 0.84 0.97 1.15 0.69 0.80
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 7.21 5.60 3.77 4.95 12 10 9.84 16 13
Total Preferred & Common Equity		 7.21 5.60 3.77 4.95 12 10 9.84 16 13
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 7.21 5.60 3.77 4.95 12 10 9.84 16 13
Common Stock		 145 147 147 150 160 160 163 176 176
Retained Earnings		 -137 -141 -143 -145 -148 -150 -153 -159 -163

Annual Metrics And Ratios for Phio Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Phio Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 65,349,121.00 6,599,846.00 23,697,338.00 18,164,356.00 26,404,670.00 5,780,592.00 13,534,692.00 13,667,973.00 2,443,447.00 1,055,219.00 10,764,428.00
DEI Adjusted Shares Outstanding		 110.00 111.00 399.00 3,058.00 4,445.00 53,524.00 125,321.00 126,555.00 271,494.00 1,055,219.00 10,764,428.00
DEI Earnings Per Adjusted Shares Outstanding		 -94,836.36 -99,720.72 -31,208.02 -2,406.80 -2,004.05 -164.30 -106.02 -90.71 -39.88 -6.78 -0.81
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -52.11% -44.12% -21.05% 820.00% -84.78% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00%
EBITDA Growth		 -16.40% 11.87% -56.35% 48.02% -21.46% 1.35% -50.14% 13.81% 5.73% 30.96% -25.44%
EBIT Growth		 -16.13% 12.01% -56.21% 47.70% -21.03% 1.28% -51.09% 13.60% 5.71% 31.81% -24.89%
NOPAT Growth		 -15.99% 11.94% -55.98% 47.63% -22.04% 2.16% -53.66% 15.17% 5.57% 31.75% -24.81%
Net Income Growth		 -16.17% 12.02% -38.45% 40.89% -21.03% 1.28% -51.09% 13.60% 5.70% 33.96% -21.65%
EPS Growth		 -16.17% 12.02% -38.45% 40.89% -21.03% 90.07% -51.09% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 5.68% -6.05% -22.60% 20.96% -14.96% -1.82% -34.72% -2.29% 11.38% 33.84% -12.19%
Free Cash Flow Firm Growth		 13.95% 1.54% -69.49% 44.79% -14.35% 0.95% -31.26% -10.55% 15.20% 32.48% -18.15%
Invested Capital Growth		 -157.16% -18.23% 14.42% 24.86% 8.51% 15.37% -107.94% 54.44% 23.31% 13.29% -34.14%
Revenue Q/Q Growth		 -29.17% 0.00% 0.00% -9.80% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% -100.00%
EBITDA Q/Q Growth		 -3.25% 3.07% 2.42% 3.61% -10.78% -12,384.51% -18,287.50% 6.77% 7.28% 2.50% -10.25%
EBIT Q/Q Growth		 -3.21% 3.11% 2.34% 3.60% -10.63% 0.00% 0.00% 5.76% 7.19% 3.03% -10.26%
NOPAT Q/Q Growth		 -3.19% 3.04% 2.42% 3.37% -11.61% 0.00% 0.00% 5.91% 7.13% 2.96% -10.29%
Net Income Q/Q Growth		 -3.15% 2.99% 2.64% 3.60% -11.70% 0.00% 0.00% 5.90% 7.17% 3.63% -9.37%
EPS Q/Q Growth		 -3.15% 2.99% 2.64% 3.60% -11.70% 0.00% 0.00% 0.00% 7.17% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.18% 2.63% -9.55% 5.71% -10.20% -0.88% 1.27% -1.97% 3.02% 12.32% -9.74%
Free Cash Flow Firm Q/Q Growth		 3.90% 2.95% -7.44% 3.93% -6.37% -8,031.38% -8,512.83% -4.00% 1.44% 13.98% -14.71%
Invested Capital Q/Q Growth		 -68.76% -50.83% 11.69% 12.27% -7.11% 15.24% -63.17% 1.59% 38.91% -48.42% -2.08%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -29,888.24% -47,136.84% -93,353.33% -5,274.64% -42,100.00% 0.00% 0.00% 0.00% -177,333.33% 0.00% 0.00%
Operating Margin		 -30,108.82% -47,447.37% -93,746.67% -5,336.23% -42,795.24% 0.00% 0.00% 0.00% -180,400.00% 0.00% 0.00%
EBIT Margin		 -30,114.71% -47,415.79% -93,820.00% -5,333.33% -42,419.05% 0.00% 0.00% 0.00% -180,400.00% 0.00% 0.00%
Profit (Net Income) Margin		 -30,067.65% -47,336.84% -83,013.33% -5,333.33% -42,419.05% 0.00% 0.00% 0.00% -180,433.33% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 88.48% 100.00% 100.00% 100.00% 100.00% 100.00% 99.94% 100.00% 100.00%
Interest Burden Percent		 99.84% 99.83% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.07% 96.87% 94.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -203.30% -91.10% -196.28% -95.52% -92.19% -93.73% -76.04% -70.06% -116.60% -114.83% -69.95%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -100.64% -73.38% -160.88% -75.80% -76.26% 0.00% 0.00% 0.00% -97.61% 0.00% 0.00%
Return on Assets (ROA)		 -100.48% -73.25% -142.35% -75.80% -76.26% 0.00% 0.00% 0.00% -97.63% 0.00% 0.00%
Return on Common Equity (ROCE)		 -203.30% -91.10% -196.28% -95.52% -92.19% -93.73% -76.04% -70.06% -116.58% -114.83% -69.95%
Return on Equity Simple (ROE_SIMPLE)		 -114.99% -82.86% -679.32% -54.21% -154.98% -67.56% -60.58% -105.92% -140.05% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.17 -6.31 -9.84 -5.15 -6.29 -6.16 -9.46 -8.02 -7.58 -5.17 -6.45
NOPAT Margin		 -21,076.18% -33,213.16% -65,622.67% -3,735.36% -29,956.67% 0.00% 0.00% 0.00% -126,280.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -48.82% -22.72% -31.45% -23.76% -23.89% -25.08% -20.06% -19.24% -31.98% -28.53% -16.99%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -98.02% -109.48% -32.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 9,841.18% 19,047.37% 26,740.00% 2,301.45% 22,419.05% 0.00% 0.00% 0.00% 72,766.67% 0.00% 0.00%
R&D to Revenue		 20,367.65% 28,500.00% 67,106.67% 3,134.78% 20,476.19% 0.00% 0.00% 0.00% 105,533.33% 0.00% 0.00%
Operating Expenses to Revenue		 30,208.82% 47,547.37% 93,846.67% 5,436.23% 42,895.24% 0.00% 0.00% 0.00% 180,400.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -10 -9.01 -14 -7.36 -8.91 -8.79 -13 -11 -11 -7.38 -9.22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -8.96 -14 -7.28 -8.84 -8.72 -13 -11 -11 -7.35 -9.22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.81 0.43 7.19 0.44 0.79 1.19 0.62 0.47 0.24 0.40 0.56
Price to Tangible Book Value (P/TBV)		 2.81 0.43 7.19 0.44 0.79 1.19 0.62 0.47 0.24 0.40 0.56
Price to Revenue (P/Rev)		 734.22 248.26 878.07 43.42 215.01 0.00 0.00 0.00 309.50 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 420.48 0.00 636.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.25 -1.20 -1.31 -1.20 -1.13 -1.12 -1.09 -1.10 -1.09 -1.11 -1.06
Leverage Ratio		 2.02 1.24 1.38 1.26 1.21 1.27 1.17 1.16 1.19 1.21 1.09
Compound Leverage Factor		 2.02 1.24 1.38 1.26 1.21 1.27 1.17 1.16 1.20 1.17 1.03
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 1.74% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 1.74% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 98.26% 100.00% 99.98% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.03 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 1.61 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.03 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.04 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 2.28 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.04 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.65 -7.07 -34.22 -6.31 -18.18 -6.64 -4.70 -14.45 -22.96 -37.84 -5.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.84 5.16 1.69 8.69 3.88 6.91 8.06 6.42 5.71 5.65 16.03
Quick Ratio		 4.68 5.08 1.58 8.53 3.69 6.49 7.84 6.08 5.20 5.30 15.69
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.08 -5.99 -10 -5.60 -6.41 -6.35 -8.33 -9.21 -7.81 -5.27 -6.23
Operating Cash Flow to CapEx		 -12,836.84% -194,000.00% -4,686.70% -150,400.00% -12,006.94% -46,326.32% -23,250.98% -10,023.97% -214,980.00% 0.00% -66,491.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -975.98 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,343.63 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,344.25 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.20 0.14 0.08 0.66 0.11 0.00 0.00 0.00 0.06 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.78 -2.10 -1.80 -1.35 -1.24 -1.05 -2.18 -0.99 -0.76 -0.66 -0.88
Invested Capital Turnover		 -0.03 -0.01 -0.01 -0.09 -0.02 0.00 0.00 0.00 -0.01 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.09 -0.32 0.30 0.45 0.12 0.19 -1.13 1.18 0.23 0.10 -0.23
Enterprise Value (EV)		 14 -8.24 9.54 -8.94 -2.47 1.49 -11 -6.74 -6.63 -3.48 -9.73
Market Capitalization		 25 4.72 13 5.99 4.52 16 14 5.08 1.86 1.90 11
Book Value per Share		 $0.14 $1.64 $0.08 $0.75 $0.22 $2.25 $1.62 $0.79 $3.16 $4.48 $1.87
Tangible Book Value per Share		 $0.14 $1.64 $0.08 $0.75 $0.22 $2.25 $1.62 $0.79 $3.16 $4.48 $1.87
Total Capital		 8.89 11 1.83 14 5.75 13 22 11 7.73 4.72 20
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.23 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.23 0.00 0.00 0.00 0.00 0.00
Net Debt		 -11 -13 -3.63 -15 -6.98 -14 -24 -12 -8.49 -5.38 -21
Capital Expenditures (CapEx)		 0.06 0.00 0.20 0.01 0.07 0.02 0.05 0.12 0.01 -0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.96 -2.39 -2.06 -1.52 -1.56 -1.33 -2.45 -1.32 -0.80 -0.66 -0.90
Debt-free Net Working Capital (DFNWC)		 8.71 11 1.57 13 5.42 13 22 11 7.69 4.72 20
Net Working Capital (NWC)		 8.71 11 1.57 13 5.42 13 22 11 7.69 4.72 20
Net Nonoperating Expense (NNE)		 3.06 2.68 2.61 2.21 2.62 2.64 3.83 3.46 3.25 1.98 2.24
Net Nonoperating Obligations (NNO)		 -11 -13 -3.63 -15 -6.98 -14 -24 -12 -8.49 -5.38 -21
Total Depreciation and Amortization (D&A)		 0.08 0.05 0.07 0.08 0.07 0.07 0.19 0.19 0.18 0.04 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -5,758.82% -12,589.47% -13,760.00% -1,103.62% -7,447.62% 0.00% 0.00% 0.00% -13,366.67% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 25,614.71% 55,600.00% 10,446.67% 9,714.49% 25,809.52% 0.00% 0.00% 0.00% 128,133.33% 0.00% 0.00%
Net Working Capital to Revenue		 25,614.71% 55,600.00% 10,446.67% 9,714.49% 25,809.52% 0.00% 0.00% 0.00% 128,133.33% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($124,740.00) ($97,416.00) ($32,788.80) ($6,177.60) ($2,087.64) ($207.36) ($112.32) ($90.90) $0.00 ($9.08) ($1.45)
Adjusted Weighted Average Basic Shares Outstanding		 110.00 371.00 437.00 3.75K 26.55K 125.30K 125.32K 126.29K 510.19K 787.47K 5.98M
Adjusted Diluted Earnings per Share		 ($124,740.00) ($97,416.00) ($32,788.80) ($6,177.60) ($2,087.64) ($207.36) ($112.32) ($90.90) $0.00 ($9.08) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 110.00 371.00 437.00 3.75K 26.55K 125.30K 125.32K 126.29K 510.19K 787.47K 11.62M
Adjusted Basic & Diluted Earnings per Share		 ($124,740.00) ($97,416.00) ($32,788.80) ($6,177.60) ($2,087.64) ($207.36) ($112.32) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 84.00 114.00 380.00 1.19K 4.27K 42.48K 118.80K 127.84K 510.19K 4.78M 11.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.17 -6.31 -9.84 -5.15 -6.29 -6.16 -9.46 -8.02 -7.49 -5.17 -6.45
Normalized NOPAT Margin		 -21,076.18% -33,213.16% -65,622.67% -3,735.36% -29,956.67% 0.00% 0.00% 0.00% -124,810.00% 0.00% 0.00%
Pre Tax Income Margin		 -30,067.65% -47,336.84% -93,820.00% -5,333.33% -42,419.05% 0.00% 0.00% 0.00% -180,533.33% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,353.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -947.10 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,353.63 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -947.73 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Phio Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Phio Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 2,443,447.00 4,591,700.00 4,591,700.00 860,721.00 1,055,219.00 4,778,154.00 4,798,154.00 5,726,750.00 10,764,428.00 11,617,250.00 11,617,250.00
DEI Adjusted Shares Outstanding		 271,494.00 510,189.00 510,189.00 860,721.00 1,055,219.00 4,778,154.00 4,798,154.00 5,726,750.00 10,764,428.00 11,617,250.00 11,617,250.00
DEI Earnings Per Adjusted Shares Outstanding		 -6.98 -4.22 -3.62 -1.77 -1.54 -0.37 -0.45 -0.42 -0.22 -0.34 -0.36
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 30.88% 38.87% 26.26% 41.82% 6.36% 12.84% -17.40% -57.42% -45.74% -119.80% -84.80%
EBIT Growth		 30.47% 38.73% 27.58% 42.81% 8.48% 14.18% -17.33% -57.55% -45.80% -119.85% -84.84%
NOPAT Growth		 30.44% 38.67% 24.85% 42.72% 11.85% 15.26% -20.64% -57.55% -51.37% -122.60% -84.84%
Net Income Growth		 30.61% 40.20% 27.58% 45.18% 14.20% 17.87% -17.33% -56.96% -45.82% -126.29% -91.04%
EPS Growth		 30.61% 40.20% 27.58% 0.00% 74.85% 0.00% 87.57% 0.00% 80.58% 0.00% 0.00%
Operating Cash Flow Growth		 12.38% 25.74% 35.87% 32.66% 42.15% 36.60% -42.94% -6.76% -51.64% -213.96% -58.86%
Free Cash Flow Firm Growth		 49.59% -35.67% -33.71% -12.12% 18.43% 56.18% 0.35% 30.40% -21.68% -221.96% -75.88%
Invested Capital Growth		 23.31% 50.90% 36.34% 64.31% 13.29% -27.21% 26.49% -95.05% -34.14% 48.65% 42.06%
Revenue Q/Q Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 32.09% -17.08% 15.09% 13.82% -9.31% -8.98% -15.71% -15.56% -1.20% -64.35% -2.50%
EBIT Q/Q Growth		 31.69% -16.22% 16.36% 13.87% -9.31% -8.98% -15.71% -15.65% -1.16% -64.33% -2.50%
NOPAT Q/Q Growth		 31.59% -16.32% 13.35% 16.93% -5.28% -11.83% -23.34% -8.49% -1.16% -64.44% -2.42%
Net Income Q/Q Growth		 31.83% -13.67% 14.30% 17.44% -6.69% -8.79% -22.44% -10.43% 0.88% -68.83% -3.37%
EPS Q/Q Growth		 31.83% -13.67% 14.30% 0.00% 0.00% 0.00% -9.76% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 18.28% 15.15% 11.64% -9.90% 29.80% 7.00% -99.22% 17.91% 0.29% -92.54% -0.80%
Free Cash Flow Firm Q/Q Growth		 8.55% -56.98% 23.74% -2.42% 33.47% 15.67% -73.40% 28.46% -16.32% -123.13% 5.28%
Invested Capital Q/Q Growth		 38.91% -14.61% -6.20% 52.00% -48.42% -68.13% 38.63% -27.35% -2.08% 35.63% 30.76%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -30,933.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -31,650.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -31,650.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -31,583.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.68% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.08% 100.00% 100.00%
Interest Burden Percent		 100.11% 97.60% 100.00% 95.85% 93.56% 93.40% 100.00% 95.49% 94.44% 96.13% 96.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -116.60% -145.23% -126.86% -122.03% -114.83% -76.12% -102.18% -107.58% -69.95% -76.36% -113.71%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -17.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -17.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -116.58% -145.23% -126.86% -122.03% -114.83% -76.12% -102.18% -107.58% -69.95% -76.36% -113.71%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -167.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.33 -1.55 -1.34 -1.11 -1.17 -1.31 -1.62 -1.75 -1.77 -2.92 -2.99
NOPAT Margin		 -22,155.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.57% -7.81% -6.31% -5.94% -6.55% -4.64% -7.11% -7.93% -4.52% -7.17% -9.68%
Return On Investment Capital (ROIC_SIMPLE)		 -17.20% -27.59% -35.51% -22.50% -24.81% -10.77% -16.01% -17.82% -8.80% -17.72% -23.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 12,766.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 16,783.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 31,650.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.90 -2.21 -1.85 -1.59 -1.74 -1.89 -2.17 -2.51 -2.53 -4.16 -4.27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.86 -2.17 -1.85 -1.59 -1.74 -1.89 -2.17 -2.50 -2.53 -4.16 -4.27
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.24 0.30 0.84 0.60 0.40 0.51 1.12 1.44 0.56 0.86 0.94
Price to Tangible Book Value (P/TBV)		 0.24 0.30 0.84 0.60 0.40 0.51 1.12 1.44 0.56 0.86 0.94
Price to Revenue (P/Rev)		 309.50 276.92 529.50 494.91 0.00 0.00 1,879.28 2,367.06 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 83.44 582.89 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.20 -1.17 -1.14 -1.11 -1.11 -1.12 -1.09 -1.06 -1.06 -1.05
Leverage Ratio		 1.19 1.28 1.29 1.27 1.21 1.14 1.20 1.17 1.09 1.08 1.13
Compound Leverage Factor		 1.20 1.25 1.29 1.21 1.13 1.07 1.20 1.12 1.03 1.04 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -19.81 -28.16 -36.90 -32.49 -34.60 -11.87 -12.57 -13.16 -4.31 -3.49 -11.71
Noncontrolling Interest Sharing Ratio		 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.71 5.48 3.47 6.38 5.65 10.58 9.36 6.90 16.03 18.32 8.39
Quick Ratio		 5.20 5.18 3.08 5.87 5.30 10.46 8.93 6.43 15.69 17.93 7.62
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.56 -2.45 -1.87 -1.91 -1.27 -1.07 -1.86 -1.33 -1.55 -3.46 -3.27
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -137,100.00% -63,750.00% -84,666.67% -29,785.71% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.06 0.07 0.08 0.08 0.00 0.00 1.50 0.92 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.76 -0.87 -0.93 -0.44 -0.66 -1.11 -0.68 -0.87 -0.88 -0.57 -0.39
Invested Capital Turnover		 -0.01 0.00 -0.01 -0.01 0.00 0.00 -0.01 -0.01 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.23 0.90 0.53 0.80 0.10 -0.24 0.25 -0.42 -0.23 0.54 0.29
Enterprise Value (EV)		 -6.63 -4.81 -1.52 -2.42 -3.48 -7.07 0.50 3.50 -9.73 -2.86 -1.09
Market Capitalization		 1.86 1.66 3.18 2.97 1.90 6.21 11 14 11 14 12
Book Value per Share		 $3.16 $2.29 $0.82 $5.75 $4.48 $11.53 $2.10 $1.72 $1.87 $1.42 $1.08
Tangible Book Value per Share		 $3.16 $2.29 $0.82 $5.75 $4.48 $11.53 $2.10 $1.72 $1.87 $1.42 $1.08
Total Capital		 7.73 5.60 3.77 4.95 4.72 12 10 9.84 20 16 13
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -8.49 -6.48 -4.70 -5.39 -5.38 -13 -11 -11 -21 -17 -13
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.80 -0.88 -0.93 -0.45 -0.66 -1.11 -0.69 -0.88 -0.90 -0.58 -0.40
Debt-free Net Working Capital (DFNWC)		 7.69 5.60 3.77 4.95 4.72 12 10 9.83 20 16 13
Net Working Capital (NWC)		 7.69 5.60 3.77 4.95 4.72 12 10 9.83 20 16 13
Net Nonoperating Expense (NNE)		 0.57 0.61 0.51 0.41 0.45 0.46 0.55 0.64 0.60 1.09 1.15
Net Nonoperating Obligations (NNO)		 -8.49 -6.48 -4.70 -5.39 -5.38 -13 -11 -11 -21 -17 -13
Total Depreciation and Amortization (D&A)		 0.04 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -13,366.67% -14,600.00% -15,483.33% -7,416.67% 0.00% 0.00% -11,450.00% -14,633.33% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 128,133.33% 93,316.67% 62,816.67% 82,416.67% 0.00% 0.00% 168,133.33% 163,783.33% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 128,133.33% 93,316.67% 62,816.67% 82,416.67% 0.00% 0.00% 168,133.33% 163,783.33% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($73.71) ($4.23) ($3.62) ($1.54) ($2.06) ($0.41) ($0.45) ($0.44) ($0.40) ($0.34) ($0.36)
Adjusted Weighted Average Basic Shares Outstanding		 25.72K 508.90K 510.19K 990.03K 787.47K 4.31M 4.79M 5.47M 5.98M 11.62M 11.62M
Adjusted Diluted Earnings per Share		 ($73.71) ($4.23) ($3.62) ($1.54) ($2.06) ($0.41) ($0.45) $0.00 ($0.40) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 25.72K 508.90K 510.19K 990.03K 4.78M 4.31M 4.79M 10.76M 11.62M 11.62M 11.62M
Adjusted Basic & Diluted Earnings per Share		 ($73.71) $0.00 $0.00 $0.00 ($2.06) $0.00 $0.00 $0.00 ($0.40) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 510.19K 510.19K 860.72K 1.06M 4.78M 4.80M 5.73M 10.76M 11.62M 11.62M 11.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.33 -1.55 -1.34 -1.11 -1.17 -1.31 -1.62 -1.75 -1.77 -2.92 -2.99
Normalized NOPAT Margin		 -22,155.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -31,683.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Phio Pharmaceuticals’ latest quarter shows a company still in development mode, with no revenue, ongoing operating losses, and continued cash burn — but it also has a much stronger cash balance than it had a year ago.

For Q1 2026, Phio reported no revenue and a net loss of $4.0 million, wider than the $2.4 million loss in Q4 2025 and the $1.8 million loss in Q1 2025. Operating expenses rose sharply year over year, driven by higher R&D and SG&A spending. At the same time, the balance sheet ended the quarter with $17.0 million in cash and equivalents, up from $10.7 million at the end of Q3 2025 and far above the $5.4 million level in Q3 2024.

  • Cash position improved significantly year over year. Cash and equivalents rose to $17.0 million in Q1 2026 from $13.3 million in Q1 2025 and $5.4 million in Q3 2024.
  • Equity financing helped support the balance sheet. Phio added cash through financing in recent periods, including a large equity raise in Q4 2025 that boosted liquidity.
  • Liabilities remain manageable. Total liabilities were only $950,000 at the end of Q1 2026, leaving the company with a solid near-term liquidity cushion.
  • Book equity remained positive. Total shareholders’ equity was $16.5 million in Q1 2026, which is a notable improvement versus earlier periods when equity was much smaller.
  • Operating cash burn remains substantial. The company used $4.0 million in operating cash during Q1 2026, compared with $2.1 million in Q4 2025 and $1.3 million in Q1 2025.
  • There is still no revenue. Phio reported zero revenue across all the periods shown, so results continue to depend on financing rather than commercial sales.
  • R&D spending is still a major driver of expenses. Research and development expense was $2.8 million in Q1 2026, up from $1.5 million in Q4 2025 and $886,000 in Q1 2025.
  • Net losses widened year over year. The Q1 2026 loss of $4.0 million was worse than the $1.8 million loss in Q1 2025.
  • Operating expenses increased materially. Total operating expenses climbed to $4.2 million in Q1 2026 from $1.9 million in Q1 2025.
  • Share dilution has been meaningful. Weighted average basic shares outstanding rose to 11.6 million in Q1 2026 from 4.3 million in Q1 2025, reflecting heavy dilution over the last year.

Bottom line: Phio’s cash balance gives it more runway than before, but the business still has no revenue and continues to burn cash at a steep rate. For retail investors, the key question remains whether the company can translate its development spending into a commercial breakthrough before dilution or further losses become a bigger problem.

08/09/26 07:52 AM ETAI Generated. May Contain Errors.

Phio Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Phio Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Phio Pharmaceuticals' net income for the last 5 years looks like this:
  • 2021: -$13.29 million
  • 2022: -$11.48 million
  • 2023: -$10.83 million
  • 2024: -$7.15 million
  • 2025: -$8.70 million
See Phio Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Phio Pharmaceuticals' total operating income in 2025 was -$9.22 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $9.22 million

Over the last 10 years, Phio Pharmaceuticals' total revenue changed from $34 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

Phio Pharmaceuticals' total liabilities were at $1.34 million at the end of 2025, a 32.0% increase from 2024, and a 40.9% decrease since 2015.

In the past 10 years, Phio Pharmaceuticals' cash and equivalents has ranged from $3.58 million in 2017 to $24.06 million in 2021, and is currently $21.03 million as of their latest financial filing in 2025.

Over the last 10 years, Phio Pharmaceuticals' book value per share changed from 0.14 in 2015 to 1.87 in 2025, a change of 1,276.2%.


Related Companies

Financial statements for NASDAQ:PHIO last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel